Blueprint, Wellcome Trust Sanger, Mass General Collaborate on Identifying Cancer Targets | GenomeWeb

NEW YORK (GenomeWeb News) – Blueprint Medicines today announced a collaboration with Wellcome Trust Sanger Institute and the Massachusetts General Hospital Cancer Center to identify new cancer targets.

The partnership will use Sanger Institute's and Mass General's extensive human cancer cell line panel and BluePrint's next-generation, highly selective kinase inhibitor compounds. Cambridge, Mass.-based Blueprint is developing the kinase inhibitors for treating genetic abnormalities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.